- Report
- March 2025
- 175 Pages
Global
From €4256EUR$4,490USD£3,555GBP
- Report
- February 2025
- 185 Pages
Global
From €4265EUR$4,500USD£3,563GBP
- Report
- January 2024
- 200 Pages
Global
From €3933EUR$4,150USD£3,286GBP
- Report
- April 2023
- 110 Pages
Global
From €4502EUR$4,750USD£3,761GBP
- Report
- April 2025
- 50 Pages
Global
From €2512EUR$2,650USD£2,098GBP
Rilpivirine is an antiretroviral drug used to treat HIV infection. It is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that works by blocking the action of the enzyme reverse transcriptase, which is needed for HIV to replicate. Rilpivirine is used in combination with other antiretroviral drugs to treat HIV infection in adults and adolescents aged 12 years and older. It is also used to prevent HIV infection in adults and adolescents aged 12 years and older who are at high risk of infection.
Rilpivirine is part of a class of drugs known as immune disorder drugs, which are used to treat a variety of conditions related to the immune system. These drugs can help to reduce inflammation, improve the body's ability to fight infection, and reduce the risk of developing certain types of cancer. Rilpivirine is used to treat HIV infection, which is an immune disorder.
Some companies in the Rilpivirine market include Janssen Pharmaceuticals, Bristol-Myers Squibb, and Gilead Sciences. Show Less Read more